



Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment

Guest Editors:

Prof. Wilbur B. Bowne

Department of Surgery, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA

Dr. Adam E. Snook

Department of Pharmacology & Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA

Deadline for manuscript submissions:

closed (30 April 2021)



Message from the Guest Editors

Dear Colleagues,

This Special Issue focuses on cancer vaccines and immunotherapy research. Submission of original articles, systematic reviews, short communications, and other types of article on related topics are welcome. Manuscripts will follow standard Journal peer-review practices, and those accepted for publication will appear in the special issue on Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment. We look forward to receiving and welcome your contributions.

keywords:

- cancer vaccines
- cancer immunotherapy
- preventive and therapeutic vaccines
- adjuvant
- combination therapy
- immune checkpoint inhibitor therapy
- monoclonal antibodies
- adoptive cancer therapy
- conventional chemotherapy/radiation therapy
- tumor microenvironment

Prof. Wilbur B. Bowne

Dr. Adam E. Snook

Guest Editors



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com